Basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process are reviewed.
Predictive sciences—built on improved computational capabilities and a deeper understanding of human physiology—are allowing researchers to perform human studies prior to, and sometimes in place of, human clinical trials in order to predict drug outcomes. Representatives of the Translational & ADME Sciences Leadership Group (TALG) in the IQ Consortium review the basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process.
Read this article in Pharmaceutical Technology's Regulatory Sourcebook March 2021 eBook.
Pharmaceutical Technology
eBook: Regulatory Sourcebook
March 2021
Pages: 24–27
When referring to this article, please cite it as H. Einolf ,et al., " Enabling the Virtual Human Through Physiologically-based Pharmacokinetic Modeling," Pharmaceutical Technology Regulatory Sourcebook eBook (March 2021).
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.